Street Watchdog Research Reiterates Its $7.50 PT on SPHS

Link to News Story
  
November 13, 2015
 
Sophiris Bio is a biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases.  The company is led by a team that has achieved more than 20 drug approvals, including several blockbusters.
 
This week the company announced that its PRX302 demonstrated a statistically significant improvement in International Prostate Symptom Score, which was the primary endpoint of the study.  “PRX302 continues to demonstrate a favorable safety profile, with no evidence of any treatment related sexual or cardiovascular side effects.”  We believe this treatment has blockbuster potential.
 
Additionally, our due diligence suggests that Sophiris has more than enough financial resources to fund operations with no additional share issuances through its next Phase III trial.
 
Disclosure:  We are long SPHS.  We do not have a financial relationship with the company.